30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers
Launched by NATIONAL EYE INSTITUTE (NEI) · Dec 21, 2007
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
Published studies have shown that treatment with oral acyclovir reduced clinical recurrences of ocular herpetic keratitis by about 40-50 %8, and treatment with valacyclovir, a more soluble prodrug of acyclovir, reduced the risk of transmission of genital herpes9, 10, 11. For this study, we will use the dose of valacyclovir that was shown effective in reducing the risk of transmission of HSV-2.9 The dose of 325 mg aspirin three times a day was chosen based on our experience with mice and other laboratory animals12. If it is effective and well tolerated at this dose, in future studies we will...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • either sex
- • any race
- • over age of 21 years
- Exclusion Criteria:
- • have active ocular herpetic lesion
- • had ocular herpetic lesion in past 30 days
- • taking systemic or oral antiviral drugs
- • have taken antiviral drugs in the past 30 days
- • taking aspirin or NSAIDs
- • have dry eyes
- • have hypersensitivity to acyclovir or valacyclovir
- • have hypersensitivity of contraindication to use of aspirin
- • have bleeding disorder
- • have GI ulcer
- • have kidney impairment
- • are pregnant or nursing
- • have participated in a clinical trial in the past 30 days
About National Eye Institute (Nei)
The National Eye Institute (NEI), part of the U.S. National Institutes of Health (NIH), is dedicated to conducting and supporting innovative research to understand, prevent, and treat eye diseases and vision disorders. As a leading sponsor of clinical trials, NEI aims to advance knowledge in ocular health through rigorous scientific inquiry and collaboration with researchers, healthcare professionals, and institutions. By fostering the development of new therapies and technologies, NEI plays a pivotal role in enhancing the quality of life for individuals affected by visual impairments and eye conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Orleans, Louisiana, United States
New Orleans, Louisiana, United States
Patients applied
Trial Officials
Herbert E Kaufman, MD
Principal Investigator
LSU Eye Center, LSU Health Sciences Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials